Prevention of gliotic scar formation by NeuroGel allows partial endogenous repair of transected cat spinal cord.
Spinal cords of adult cats were transected and subsequently reconnected with the biocompatible porous poly (N-[2-hydroxypropyl] methacrylamide) hydrogel, NeuroGel. Tissue repair was examined at various time points from 6-21 months post reconstructive surgery. We examined two typical phenomena, astrogliosis and scar formation, in spines reconstructed with the gel and compared them to those from transected non-reconstructed spines. Confocal examination with double immunostaining for glial fibrillary acidic protein (GFAP) and myelin basic protein (MBP) showed that the interface formed between the hydrogel and the spine stumps did prevent scar formation and only a moderate gliosis was observed. The gel implant provided an adequate environment for growth of myelinated fibers and we saw angiogenesis within the gel. Electron microscopy showed that regenerating axons were myelinated by Schwann cells rather than oligodendrocytes. Moreover, the presence of the gel implant lead to a considerable reduction in damage to distal caudal portions of the spine as assessed by the presence of more intact myelinated fibers and a reduction of myelin degradation. Neurologic assessments of hindlimb movement at various times confirmed that spinal cord reconstruction was not only structural but also functional. We conclude that NeuroGel lead to functional recovery by providing a favorable substrate for regeneration of transected spinal cord, reducing glial scar formation and allowing angiogenesis.
Woerly
Stéphane
S
Organogel Canada Ltée, Sainte-Foy, Québec, Canada.
Doan
Van Diep
VD
Organogel Canada Ltée, Sainte-Foy, Québec, Canada.
Sosa
Norma
N
Mental Retardation Research Center, Neuropsychiatric Institute, David Geffen School of Medicine at UCLA, Los Angeles, California.
de Vellis
Jean
J
Mental Retardation Research Center, Neuropsychiatric Institute, David Geffen School of Medicine at UCLA, Los Angeles, California.
Espinosa-Jeffrey
Araceli
A
Mental Retardation Research Center, Neuropsychiatric Institute, David Geffen School of Medicine at UCLA, Los Angeles, California.
D000818:Animals; D001672:Biocompatible Materials / Q000494:pharmacology / Q000627:therapeutic use; D002415:Cats; D002921:Cicatrix / Q000503:physiopathology / Q000517:prevention & control*; D005260:Female; D005904:Glial Fibrillary Acidic Protein / Q000378:metabolism; D005911:Gliosis / Q000503:physiopathology / Q000517:prevention & control*; D006614:Hindlimb / Q000294:innervation / Q000502:physiology; D020100:Hydrogels / Q000494:pharmacology* / Q000627:therapeutic use; D008689:Methacrylates / Q000494:pharmacology / Q000627:therapeutic use; D008854:Microscopy, Electron; D009043:Motor Activity / Q000187:drug effects / Q000502:physiology; D004676:Myelin Basic Protein / Q000378:metabolism; D009186:Myelin Sheath / Q000187:drug effects / Q000378:metabolism / Q000648:ultrastructure; D018919:Neovascularization, Physiologic / Q000187:drug effects / Q000502:physiology; D009413:Nerve Fibers, Myelinated / Q000187:drug effects / Q000502:physiology / Q000648:ultrastructure; D009416:Nerve Regeneration / Q000187:drug effects* / Q000502:physiology; D020127:Recovery of Function / Q000187:drug effects / Q000502:physiology; D012583:Schwann Cells / Q000187:drug effects / Q000502:physiology / Q000648:ultrastructure; D013119:Spinal Cord Injuries / Q000188:drug therapy* / Q000473:pathology / Q000503:physiopathology; D016896:Treatment Outcome
D001672:Biocompatible Materials; D005904:Glial Fibrillary Acidic Protein; D020100:Hydrogels; D008689:Methacrylates; D004676:Myelin Basic Protein; C032802:hydroxypropyl methacrylate